Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 17/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7077016 | 0.91 | CALML3 (0.41) | GRM2 | |
| SCHEMBL5233795 | 0.86 | GRM2 (0.40) | GRM2DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL5833839 | 0.83 | CALML3 (0.48) | GRM2DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL5233293 | 0.83 | CALML3 (0.48) | GRM2DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL7084898 | 0.82 | GRM2 (0.42) | GRM2 | |
| SCHEMBL7084897 | 0.82 | GRM2 (0.42) | GRM2 | |
| SCHEMBL7081042 | 0.81 | GRM2 (0.41) | GRM2DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL4011956 | 0.81 | GRM2 (0.42) | GRM2DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL4305527 | 0.81 | GRM2 (0.40) | GRM2DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL5834101 | 0.81 | GRM2 (0.40) | GRM2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6617339-B1 | 5-Isoxazolyloxymethyl-3-((dihydroxypropanoyl)-4-tetrahydropyri dyl-3,5- difluorophenyl)oxazolidinone, or the phosphated derivative or its disodium salt; antibiotic with useful activity against Grampositive pathogens | SYNGENTA LIMITED (GB) | 2003-09-09 | — | — | US | disclosed |
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | SYNGENTA LIMITED (GB) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | CYP3A5, CYP2D6, OXA1L | GRM2 3844/4885DRD2 835/4885DRD4 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.